BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23985254)

  • 1. [Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy].
    Qiao Y; Ren H; Huang Y; DU ZL; Yu DK; Jin J; Li YX; Lin DX; Tan W
    Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):268-72. PubMed ID: 23985254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
    J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate.
    Feng YR; Jin J; Ren H; Wang X; Wang SL; Wang WH; Song YW; Liu YP; Tang Y; Li N; Liu XF; Fang H; Yu ZH; Li YX
    BMC Cancer; 2017 Mar; 17(1):182. PubMed ID: 28279170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Feasibility study on Xelox (capecitabine plus oxapliplatin) in the volumetric modulated arc therapy (VMAT)-based preoperative chemoradiotherapy for locally advanced rectal cancer].
    Xiao L; Huang R; You K; Chang H; Qiu B; Xiao W; Chen L; Gao Y; Liu M
    Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Mar; 17(3):219-24. PubMed ID: 24671807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of Genetic Variations in MicroRNA Seed Regions With Acute Adverse Events and Survival in Patients With Rectal Cancer Receiving Postoperative Chemoradiation Therapy.
    Huang Y; Feng Y; Ren H; Zhang M; Li H; Qiao Y; Feng T; Yang J; Wang W; Wang S; Liu Y; Song Y; Li Y; Jin J; Tan W; Lin D
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):1026-1033. PubMed ID: 29485044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
    Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
    Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer.
    Hong TS; Moughan J; Garofalo MC; Bendell J; Berger AC; Oldenburg NB; Anne PR; Perera F; Lee RJ; Jabbour SK; Nowlan A; DeNittis A; Crane C
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):29-36. PubMed ID: 26163334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
    Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
    J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
    Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt.
    Formica V; Benassi M; Del Vecchio Blanco G; Doldo E; Martano L; Portarena I; Nardecchia A; Lucchetti J; Morelli C; Giudice E; Rossi P; Anselmo A; Sileri P; Sica G; Orlandi A; Santoni R; Roselli M
    Med Oncol; 2018 May; 35(6):83. PubMed ID: 29721745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy.
    Lund JL; Sturmer T; Sanoff HK
    J Geriatr Oncol; 2016 May; 7(3):176-86. PubMed ID: 26926829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
    Gao YH; An X; Sun WJ; Cai J; Cai MY; Kong LH; Lin JZ; Liu GC; Tang JH; Wu XJ; Chen G; Pan ZZ; Ding PR
    J Surg Oncol; 2014 Apr; 109(5):478-82. PubMed ID: 24288203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
    Yeo SG; Kim DY; Park JW; Choi HS; Oh JH; Kim SY; Chang HJ; Kim TH; Sohn DK
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):856-62. PubMed ID: 21300482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.
    Bajetta E; Pietrantonio F; Buzzoni R; Ferrario E; Valvo F; Mariani L; Dotti KF; Biondani P; Formisano B; Gevorgyan A; Grassi P; Di Bartolomeo M
    Am J Clin Oncol; 2014 Dec; 37(6):545-9. PubMed ID: 23428953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Short-term efficacy comparison between preoperative three dimensional conformal radiotherapy and volumetric modulated arc therapy concurrently combined with chemotherapy in the treatment of locally advanced rectal carcinoma].
    Xiao L; Yu X; Zhu Y; Xiao W; Zeng Z; Liu M; Zhang R; Gao Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jul; 19(7):769-75. PubMed ID: 27452754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer.
    Jin T; Zhu Y; Luo JL; Zhou N; Li DC; Ju HX; Fan YT; Liu Y; Zhu YP; Feng HY; Liu LY
    Int J Colorectal Dis; 2015 Mar; 30(3):337-45. PubMed ID: 25564344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
    J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of Genetic Variations in Mismatch Repair Genes MSH3 and PMS1 with Acute Adverse Events and Survival in Patients with Rectal Cancer Receiving Postoperative Chemoradiotherapy.
    Yang J; Huang Y; Feng Y; Li H; Feng T; Chen J; Yin L; Wang W; Wang S; Liu Y; Song Y; Li Y; Jin J; Tan W; Lin D
    Cancer Res Treat; 2019 Jul; 51(3):1198-1206. PubMed ID: 30590005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Genetic variations in apoptosis genes are associated with acute adverse events in postoperative rectal cancer patients receiving concurrent chemoradiotherapy].
    Yin LL; Yang J; Feng YR; Huang Y; Feng T; Chen JN; Chen HX; Lin DX; Li YX; Jin J; Tan W
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):376-382. PubMed ID: 32482026
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.